AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 11 min read$UTHR

MAHON PAUL A sold $4.7M of UTHR

MAHON PAUL A (EVP & GENERAL COUNSEL) sold 8,300 shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $564.95 ($558.30–$573.15, $4.69M total) across 10 trades on 2026-10-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · MAHON PAUL A
Published Oct 1, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 9:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UTHR
Neutral
medium confidence
Mentioned
$UTHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRNeutralLow
01

Why it matters

The transaction is a primary disclosure but modest in size; it may cause slight short‑term pressure but is unlikely to move the stock materially.

02

Market read

Primary insider filing; modest relevance for short‑term traders monitoring insider activity.

03

What to watch

The 10b5‑1 plan may have been set up before any material news, reducing the informational value of the transaction.

Relevance 5/10Novelty 4/10Timing: post‑market 2026‑10‑01

Background

United Therapeutics (NASDAQ: UTHR) filed a Form 4 reporting an insider sale by its EVP & General Counsel under a pre‑arranged 10b5‑1 plan.

Company-level read

Ticker impact

$UTHRNeutralMedium confidence
Context

SEC Form 4 shows EVP & General Counsel Paul Mahon sold 8,300 shares for $4.69M via a 10b5‑1 plan.

Expected impact

likely slight downward pressure as the market prices the insider sell

Evidence & confidence

A C‑suite insider sold shares worth under $5M using a pre‑arranged plan; such sales typically have limited impact but can signal short‑term weakness.

Market effects

Sector

Minimal effect on the biotech/therapeutics sector; the sale is company‑specific.

Regional

No broader regional impact.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event and not indicative of any negative fundamentals.

Key entities

  • company
    United Therapeutics Corp

    Biopharma company listed on NASDAQ (UTHR).

  • insider
    Paul Mahon

    EVP & General Counsel of United Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UTHR insider trading history →

Related articles

OCT 28
$UTHRMed

United Therapeutics Receives FDA Clearance to Begin Clinical Trial of Inhaled PAH Treatment

United Therapeutics (UTHR) received FDA clearance to start clinical trials for Treprostinil-Iloprost SMI, an inhaled treatment for pulmonary arterial hypertension (PAH). The phase 1 trial will assess safety and tolerability. The therapy aims to address symptom flare-ups between maintenance doses. UTHR plans a phase 2 trial in 2027 if initial results are positive. PAH affects around 500,000 people globally.

finance.yahoo.com2 min
OCT 28
$UTHRMed

FDA clears a trial of a two-drug inhaler that could be the first as-needed therapy for lung artery disease.

The FDA approved a trial for Treprostinil-Iloprost SMI, a potential first as-needed inhaler therapy for pulmonary arterial hypertension (PAH). United Therapeutics plans a phase 1 study in 2026, with a phase 2 study in PAH patients anticipated in 2027. The therapy combines treprostinil and iloprost, aiming to provide episodic symptom relief. United Therapeutics aims to expand its PAH treatment portfolio.

stocktitan.net2 min